David Schilansky, COO of DBV Technologies SA – ADR (DBVT), says the revenue side of the company is very simple. DBVT is a loss-making company and does not generate any significant revenues.
“We do benefit from what we call credit tax research, which is really a tax inflow from the French government related to the spend to the R&D expenditures, but this is the only source of revenue that we have, and it’s about 4 million euro per year, so it’s really nonsignificant at this stage,” he says.
Schilansky says the company burned roughly 3.5 to 4 million euro per month last year and this year to date. He says that burn rate will accelerate in the future as DBVT intensifies the number of clinical studies it is running.
“We’re also setting up a commercial infrastructure in the U.S., but we’re not giving precise numbers,” he says. “What we have said about our current cash position is that close to 300 million euro will finance DBV until the launch of the product in the U.S.”
Interview Highlights: Harry Burn III and Mayo T. Smith of Sound Shore Management on Investing Strategies
January 19, 2017
Long-Term Earnings Growth for Nestle SA (ADR) (OTCMKTS:NSRGY) and Danone SA (ADR) (OTCMKTS:DANOY)
May 26, 2016
Chipotle Mexican Grill (CMG) Expected to Accelerate Sales in Q2, Sees Expansion Potential with ShopHouse Brand
March 20, 2013
CME Group (CME) Revenues to Accelerate When Interest Rates Rise; Will Benefit from Regulation of OTC Derivatives
April 02, 2013
21st Century Cures Act Likely to Accelerate Demand for Medidata Solutions Inc (MDSO)
November 03, 2015
